Screener
Protagonist Therapeutics PTGX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Income taxes payable | — | (2,689) |
| Operating lease liability | (1,107) | 104 |
| Other non-current asset | (832) | — |
| Net cash provided by operating activities | 170,109 | 96,583 |
| Cash Flows from Investing Activities | ||
| Purchase of marketable securities | (203,644) | (281,194) |
| Proceeds from maturities of marketable securities | 289,105 | 235,957 |
| Proceeds from sale of marketable securities | 3,384 | 7,003 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Protagonist Therapeutics's operating cash flow?
- Protagonist Therapeutics (PTGX) reported operating cash flow of $219.05M in Q2 2026.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Protagonist Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude